SPOTLIGHT -
The Role of Venetoclax for Treatment of AML
Renowned experts in hematology-oncology provide insight into the practical implications of treating acute myeloid leukemia with the current standard-of-care regimen using venetoclax.
Read More
Future Treatment Landscape of AML
Corey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.
Maintenance Therapy Post-Transplant in AML
Patient selection for maintenance therapy post-allogeneic transplant in myeloid malignancies and thoughts on treatment of FLT3-mutated disease post-transplant with agents such as midostaurin.
Use of APR-246 and Oral HMAs in AML
Role of Transplant in AML
Use of Omidubicel Therapy in Hematologic Malignancies
BMT CTN 1102 Study in High-Risk MDS
Novel Targets and Biomarkers in AML
IDH1/2-Mutated Treatment-Naïve AML
BCL2 Inhibition in AML: VIALE-A Study
Type 1/2 FLT3 Inhibitors in AML
Role of Dual Targeted Therapy in AML
Sequencing of FLT3 Inhibitors in AML
Management of AML: FLT3 Inhibitors and BCL2 Inhibitors
Role of FLT3 Inhibitors in Chemo-Ineligible AML
MRD Monitoring in FLT3 ITD AML
Assessing MRD Status in AML
Prognostic Significance of IDH Mutations in AML
FLT3 Testing for Treatment of AML
Molecular Testing in Community Practices
Role of Molecular Testing in AML
Progress in the Treatment of AML
Implications for Treating AML With CC-486
CC-486 Maintenance Therapy in AML
Gemtuzumab for AML
CPX-351 in Newly Diagnosed Secondary AML
Differentiation Syndrome and IDH Inhibitors in AML
IDH Inhibitors and MDS
IDH1/2 Inhibitors for AML
IDH Mutations in AML
ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting
Sacituzumab Govitecan Elicits Consistent Safety in Patients With HR+/HER2– Breast Cancer, Regardless of UGT1A1 Status
Atezolizumab Plus Trastuzumab/Vinorelbine Elicits Responses in HER2+ Advanced Breast Cancer
Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities